Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Almac Discovery Licenses Cancer Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Almac Discovery Licenses Cancer Drug

Shin Poong to develop and market ALM201 in South Korea

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Almac Discovery has licensed its novel anti-angiogenic peptide ALM201 to Shin Poong Pharmaceutical Co. Ltd. for clinical development and marketing in South Korea. Almac will receive an undisclosed upfront payment, milestones and royalties. Almac Discovery will pursue its own development program in Europe and is seeking partners for ALM201 in all other territories.
 
ALM201 is a highly potent anti-angiogenic peptide targeted to cells expressing CD44 and acts by inhibiting migration of vascular endothelial cells. The compound has completed preclinical development with a good toxicology profile and is entering Phase I/II trials in the UK.
 
Stephen Barr, president and managing director of Almac Discovery, said, “We are delighted to be partnering with Shin Poong. Their work on ALM201 in South Korea will complement our own program very well and will add significant scientific value.”
 
Mr. Won June Chang, chief executive officer of Shin Poong, said, “We are delighted to license the novel and innovative anti-cancer drug candidate from Almac Discovery and we look forward to supporting the development of this drug candidate in South Korea.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics